CLEC-2 has been recently described as playing crucial roles in thromobosis/hemostasis, tumor metastasis, and lymphangiogenesis based on the following findings. The snake venom rhodocytin is known as a strong platelet activator, and this effect has been shown to be mediated by CLEC-2 by us. Podoplanin, which is expressed on the surface of tumor cells, is an endogenous ligand for CLEC-2 and facilitates tumor metastasis by inducing platelet aggregation. Mice deficient in podoplanin, which is also expressed on the surface of lymphatic endothelial cells, show abnormal patterns of lymphatic vessel formation. In this study, we, for the first time, report on the generation and phenotype of CLEC-2-deficient mice. These mice are lethal at the embryonic and neonatal stage associated with disorganized and blood-filled lymphatic vessels and severe edema. Moreover, using transplantation of fetal liver cells from the CLEC-2-/-or CLEC-2+/+ embryos, we were able to demonstrate that CLEC-2 is involved in thrombus stabilization in vitro and in vivo, possibly through homophilic interactions without apparent increase in bleeding tendency. We propose that CLEC-2 could be an ideal novel target protein for an anti-platelet drug, which inhibits pathological thrombus formation, but not physiological hemostasis.
The C-type lectin receptors are now established as multifunctional molecules in the field of cell adhesion, endocytosis, and pathogen recognition (1,2). C-type lectin-like receptor-2 (CLEC-2) 1 has been recently described as playing crucial roles in thromobosis/hemostasis, tumor metastasis, and lymphangiogenesis, based on the following findings, mainly reported by us. i) The snake venom rhodocytin is known as a strong platelet activator, and this effect has been shown to be mediated by CLEC-2 (3); ii) podoplanin is an endogenous ligand for CLEC-2, is expressed on the surface of tumor cells, and facilitates tumor metastasis by inducing platelet aggregation (4, 5) ; iii) mice deficient in podoplanin, which is expressed on the surface of lymphatic endothelial cells, show defects in lymphatic vessel pattern formation (6) .
We have also reported that an anti-podoplanin antibody which blocks CLEC-2/podoplanin interaction inhibits tumor metastasis by experimental lung metastasis model in mice, suggesting that CLEC-2 facilitates tumor metastasis through association with podoplanin (7) . However, podoplanin is also expressed on the surface of lymphatic endothelial cells, kidney podocyte, and type I alveolar cells (8, 9) . We previously found that podoplanin on the surface of lymphatic endothelial cells also induced platelet aggregation (4, 5) . The physiological significance of this receptor-ligand interaction remains to be elucidated since lymphatic endothelial cells are not in direct contact with platelets under the physiological conditions. However, it may be of great importance during organ development or under pathological conditions. It was previously reported that podoplanin-deficient mice have defects in lymphatic vessel pattern formation (6) . Intracellular signaling molecules, spleen tyrosine kinase (Syk) and SH2 domain containing leukocyte protein of 76kDa (SLP-76) in platelets are requisites for rhodocytin-induced platelet activation mediated through CLEC-2 (3) and regulate blood and lymphatic vascular separation, although these signaling molecules are not detected in endothelium (10) . This finding implies that Syk and SLP-76 work by way of blood cells. Moreover, blood/lymphatic misconnection is observed in mice deficient in endothelial cell O-glycan (11) , the presence of which is required for podoplanin-induced platelet aggregation (4) . These findings taken together lead to a hypothesis that podoplanin-induced platelet activation through CLEC-2 may regulate proper formation of lymphatic vessels.
To address this issue, generation of CLEC-2-deficient mice has been ardently awaited.
Powerful platelet-activating ability of CLEC-2 and its relatively specific expression in platelets and megakaryocytes imply that CLEC-2 also plays an important role in thrombosis and hemostasis.
However, neither podoplanin nor rhodocytin can stimulate platelets within blood vessels. In addition, CLEC-2 ligands that play a role in thrombosis and hemostasis is not known. Therefore, generation of CLEC-2-deficient mice has been awaited to reveal a role of CLEC-2 in thrombosis and hemostasis.
In this study, we, for the first time, report on the generation and phenotype of CLEC-2-deficient mice. These mice are lethal at the embryonic/neonatal stage with blood/lymphatic misconnections. Moreover, using transplantation of fetal liver cells from the CLEC-2-/-or CLEC-2+/+ embryos, we were able to demonstrate that CLEC-2 is involved in thrombus stabilization, possibly through homophilic interactions.
Experimental Procedures

Generation of Mice
This study was approved by Institutional Animal Care and Use Committee (approval No. ) and the Committee on Genetic Engineering (approval No. in the University of Yamanashi. A targeting vector to generate CLEC-2-deficient mice was designed so that a part of exon 1 flanked by two loxP sites could be deleted by expression of Cre protein (Supple. Figure 1A ). ES cells from C57BL/6 were transfected with this targeting vector, G418-resistant clones were screened by PCR, and positive clones were subjected to Southern blot analysis using a 3' probe (Supple. Figure 1A , 1B). Nine ES clones were obtained containing the appropriately targeted disrupted allele and injected into blastcycts. Germline transmission confirmed by PCR and Southern blot was obtained from 6 independent ES cell clones (hereafter CLEC-2 flox/+). We crossed a CLEC-2 flox/+ mouse with a mouse that systemically expresses Cre recombinase to generate CLEC-2+/-mice. The heterozygous mice were phenotypically normal and were bred to obtain homozygous mice for the allele containing disrupted exon 1 of the CLEC-2 gene. For analysis of genotypes of CLEC-2 floxed mice, DNA was subjected to 30 cycles of amplification with each cycle consisting of 20 sec at 94ºC and 7 min at 62 ºC followed by an extension of 10 min at 74 ºC on a thermal cycler using primers long F2 & exon R and PCR products were separated by 7.5% acrylamide gels (Supple. Figure 1A) . The wild-type allele gave a 229-bp band, whereas the floxed allele gave a 269-bp band by primers b and c (Suppl. Figures 1C) . For analysis of genotypes of CLEC-2 null mice, DNA was subjected to 30 cycles of amplification with each cycle consisting of 20 sec at 94ºC and 7 min at 60 ºC followed by an extension of 10 min at 74 ºC on a thermal cycler using primers long F1 & exon R (733-bp band) for wild type allele and neo R and long F2 (871-bp band) for deleted allele and PCR products were separated by 0.8% agarose gels (Supple. Figure  1A , 1D).
Lymphangiography
To visualize functional lymphatic vessels, FITC-dextran (Sigma, MW=2000 kDa, 8 mg/ml in PBS) was injected subcutaneously into the back of the embryonic forelimb. Lymphatic flow carrying FITC-dextran in embryos was analyzed by fluorescence microscopy (12) .
Microscopy
Embryos were photographed at autopsy. For routine histology, embryos were fixed with 3.7% formalin and embedded in paraffin. Sections were stained with H&E.
For immunohistochemistry, deparaffinized sections were stained with rabbit anti-mouse Lyve-1 (Abcam Inc.) using Simplestain® mouse MAX-PO (Rabbit) (Nichirei) according to manufacturer's instruction.
For confocal microscopy, embryos (E17.5) were fixed in 4% PFA (paraformaldehyde) at room temperature for overnight, washed, cryoprotected with 10% sucrose for 2 hours, 20% sucrose for 2 hours, and 40% sucrose for overnight. The samples were then mounted in OCT compound (Sakura Finetek). Cryosections (approximately 10 μm) were incubated with biotin-conjugated goat anti-mouse Lyve-1 (R&D), rat anti-mouse platelet endothelial cell adhesion molecule (PECAM)-1 mAb (clone MEC13.3, BD), and Cy3-conjugated anti-α smooth muscle actin (SMA) mAb (clone 1A4, Sigma-Ardrich) for overnight at 4°C, developed with streptavidin Cy5 (Invitrogen) and Alexa Fluor 488-conjugated donkey anti-rat IgG (Invitrogen) for 2 hours at room temperature, and mounted with ProLong Gold mounting medium. The samples were analyzed by confocal laser-scanning microscopy using an OLYMPUS FV-1000 microscopy (Olympus Corporation).
For immunohistochemical analysis of embryonic back skin, whole embryos were dissected between E14.5 and E17.5 and fixed in 4% paraformaldehyde (PFA)/PBS at 4 °C for overnight. The back skin was peeled off and further fixed in 4% PFA/PBS at 4 °C overnight. Tissues were washed in PBS with 0.2% Triton X-100 (PBT) at 4 °C for 30 min twice, blocked in PBT containing 1% bovine serum albumin at room temperature for 1 h, and stained with antibodies against American hamster anti-mouse PECAM-1 (clone 2H8, Chemicon), rabbit anti-mouse Lyve-1 (RELIATech), rat anti-mouse Ter-119 (clone Ter-119, BD) in blocking solution at 4 °C overnight. Tissues were washed in PBT for 30 min 3 times at 4 °C and twice at room temperature, followed by staining with Cy3-conjugated anti-American hamster IgG and Cy5-cnjugated anti-rat IgG (Jackson immunoResearch) or Alexa Fluor 488-conjugated anti-rabbit IgG (Invitrogen) in blocking solution at 4 °C overnight. Tissues were washed in PBT for 30 min 3 times at 4 °C and twice at room temperature. Back skin was flat-mounted on slide glasses in ProLong Antifade (Invitrogen). Confocal microscopy was carried out on an Olympus FV-1000 (Olympus).
Fetal liver transplantation
CLEC-2-deficient radiation chimeric mice were generated as follows.
Seven-to ten-week-old C57BL/6 male mice, which had been kept on acidified water for a week and then kept on 0.017% enrofloxacin in water for 3 days, were given two irradiations of 500 rads from a 60Co source 3 h apart (13) . The mice were then rescued by intravenous injection of 1.0 × 10 6 fetal liver cells from CLEC-2-/-or control embryos at E13.5. The reconstituted mice were kept on 0.017% enrofloxacin in water for 3 weeks following irradiation and were used for experiments no less than 7 weeks following irradiation.
Platelet Preparation
Murine blood was drawn from mice, which were terminally anesthetized by diethyl ether, by portal vein puncture, and taken into 100 μl of acid citrate dextrose. Washed murine platelets were obtained by centrifugation as described previously, using prostacyclin to prevent activation during the isolation procedure (14) . Washed platelets were resuspended in modified Tyrode's buffer (14) at the indicated cell densities.
Generation of rabbit anti-mouse CLEC-2 antibody
Recombinant extracellular domain of mouse CLEC-2 expressed as a dimeric rabbit immunoglobulin Fc domain fusion protein (mCLEC-2-rFc2) was generated as described previously (4) . A purified polyclonal Ab, specific for mouse CLEC-2, was purified by protein A Sepharose (GE Healthcare) from the serum of Japanese White Rabbit after 6 times immunization with mCLEC-2-rFc2.
Western blotting
Western blot was performed as described previously (14) . Briefly, murine washed platelets (2.0 × 10 8 /ml) were dissolved with SDS sample buffer, separated by 4-12% SDS-PAGE, electrotransferred, and Western blotted by anti-mouse CLEC-2 antibody.
Platelet aggregation
Rhodocytin was purified as described previously (15) . Poly PHG, a specific GPVI agonist, was generated as described previously (16) . A quantity of 300 μl washed platelets (2.0 × 10 8 /ml) from CLEC-2-chimera or WT-chimera was used for aggregation studies. The washed platelets were stimulated by rhodocytin (20 nM), collagen (1 μg/μl, Horm), U46619 (0.5 μM, Merck), ADP (5 μM, MC Medical), PAR-4 (50 μM, Sigma) and platelet aggregation was monitored by light transmission using a Born aggregometer (PA-100, Kowa) with high-speed stirring (1200 rpm) at 37°C for 10 min.
Flowcytometory
Whole blood drawn from mice as described above was diluted to 15 times by modified Tyrode's buffer. 25 μl of the diluted whole blood were incubated with Cy2-labeled anti-mouse CLEC-2, Cy2-labeled control rabbit IgG, PE-labeled control rat IgG (Emfret), FITC-labeled control rat IgG (Emfret), FITC-labeled anti-mouse glycoprotein (GP) VI (Clone: JAQ-1, Emfret), FITC-labeled anti-mouse integrin αIIb (Emfret), PE-labeled anti-mouse GPIbα (Emfret), FITC-labeled anti-mouse PECAM-1 (BD), PE-labeled anti-mouse integrin α2 (Clone: HMα2, BD), FITC-labeled control hamster IgG (Serotec), and FITC-labeled integrin β1 (Serotec) for 15 min at room temperature. For analysis of activated integrin αIIbβ3, 25 μl of diluted whole blood were stimulated with the indicated platelet agonists (20 nM rhodocytin, 20 μg/ml Poly PHG, 50 μg/ml collagen, 50 μM U46619, 40 μM ADP, 100 μM PAR-4) for 5 min at room temperature followed by addition of anti-activated mouse integrin αIIbβ3 (Clone: JonA, Emfret) for 5 min at room temperature. For analysis of CD62P expression, 25 μl of washed platelets (5 × 10 7 /ml) were used. Reactions were terminated by addition of 400 μl of PBS and then, the samples were analyzed by FACScan (BD) and a CellQuest software (BD). For detection of soluble mCLEC-2-rFc2 binding to platelets, WT or CLEC-2-deficicent platelets (3 × 10 8 /ml) were stimulated with or without 50 μM PAR-4 peptides for 5 min under non-stirring condition. Then, they were incubated with 50 μg/ml of the recombinant mouse CLEC-2-rabbit Fc2 or rabbitFc2 for 20 min. After washing with modified Tyrode's buffer, those cells were resuspended with 100 μl of PBS and stained with 2 μl of FITC-labeled anti-rabbit IgG (BD) for 15 min. Stained cells were analyzed immediately using a FACScan and CellQuest software (BD). Where indicated, quantification of the soluble protein binding was performed using median fluorescence intensity and the data were expressed mean plus or minus S.E..
Measurement of Serotonin release
Washed platelets (3 × 10 8 /ml) from WT or CLEC-2-chimeras were stimulated with or without 20 nM rhodocytin, 20 μg/ml of poly PHG, or 50 μg/ml of collagen for 5 min under non-stirring condition. After spinning down platelets, serotonin concentration of the 15 μl of the supernatant was measured using 5HT ELISA kit (DLD DIAGNOSTIKA GmBH) according to the manufacturer's instruction.
Platelet adhesion assay
Coverslips were coated with 50 μg/ml of laminin, 50 μg/ml of collagen, or 200 μg/ml of fibrinogen, 100 μg/ml of VWF, 250 μg/ml of rFc2, or 250 μg/ml of mouse CLEC-2-rFc2 overnight at 4°C. After twice washing with PBS, the coverslips were blocked with 1% fatty acid-free purified BSA in PBS for 2 hours at room temperature and then rinsed by modified Tyrode buffer. BSA-coated coverslips were prepared for negative control. Washed murine platelets (3.0 × 10 7 /ml) were seeded on the coverslips for 30 min at room temperature in the presence or absence of 10 μM ADP. After removal of unbound platelets, coverslips were washed with modified Tyrode buffer, and then adherent platelets were fixed by 3% paraformaldehyde for 30 minutes at room temperature, permeabilized by 0.3% Triton X-100 for 5 minutes, and stained by TRITC-conjugated phalloidin for 2 hours as described elsewhere (17) . Platelets were visualized by an inverted fluorescent microscope IX71 (Olympus) equipped with a 100×/1.30 objective lens, a monochromatic light source, and a DP-70 digital camera (Olympus). At least 6 images from 2 independent experiments were chosen at random per experiment and analyzed by 2 individuals, 1 of whom performed the analysis under blind conditions. The analysis involved both counting of adhered platelets (0.006 mm2 per image) and the analysis of platelet surface area using NIH image (National Institutes of Health [NIH], Bethesda, MD) for Macintosh. Statistical significance was evaluated by the Student's t test. In each case, P values of less than 0.05 were taken as the minimum to indicate statistical significance.
Flow Adhesion Assay
Whole blood from WT-chimeras or CLEC-2-chimeras was collected into a syringe and anticoagulated with 40 μM PPACK and 5 units/ml heparin. Capillary tubes (0.3 × 1.2 mm, 50 mm long) were coated with 50 μg/ml collagen overnight at 4 °C. Capillaries were washed and blocked with phosphate-buffered saline containing 2% BSA for 2 h at room temperature.
Then they were rinsed with modified Tyrode's buffer supplemented with 2 mM CaCl 2 and 1 units/ml heparin and connected to a syringe filled with the anticoagulated blood that had been pretreated with 5 μM DiOC6 for 30 min. Blood was perfused into capillaries at 2000 S -1 and adherent platelets were visualized using a fluorescent video microscope (IX71, Olympus). Where indicated, 10 μM ADP was coinfused with anticoagulated blood shortly before entering the capillary tubes. Movie data were converted into sequential photo images. For measurement of thrombus volume, capillaries with thrombus were visualized using a FV1000 confocal microscopy (Olympus). The data were analyzed by Fluoview software (Olympus) and thrombus volume were expressed as integrated fluorescent intensity. Platelet concentrations were counted 1 week before the experiments so that platelet counts were same between WT-chimeras and CLEC-2-chimeras.
Intravital microscopy and thrombus formation.
To visually analyze thrombus formation in the microcirculation of the mesentery in living animals, we used in vivo laser injury and visualization techniques developed through modification of conventional methods (18, 19) . Male mice were anesthetized by injection with urethane (1.5 g/kg), and a small incision was made so that the mesentery could be observed without being exteriorized. FITC-dextran (5 mg/kg BW) was injected into mice to visualize cell dynamics, while hematoporphyrin (1.8 mg/kg for capillary thrombi, 2.5 mg/kg for arterioles) was injected to produce reactive oxygen species upon laser irradiation. Blood cell dynamics and production of thrombi were visualized during laser excitation (wavelength 488 nm, 30 mW power). Sequential images were obtained for 20 seconds at 30 frames/s using a spinning-disk confocal microscope (CSU-X1, Yokogawa Electronics) and an EM-CCD camera (iXon, Andor). Platelet concentrations were counted 1 week before the experiments so that platelet counts were same between WT-chimeras and CLEC-2-chimeras.
Tail bleeding
Mice were anaesthetized with 3.5% sevoflurane and 0.5 l/min O 2 through a face mask, throughout the experiment. We laid the mice on its stomach and arranged the tail lying horizontally with the tip hanging over the edge of the bench. We then cut off the tip of the tail (1 mm in length) with a sharp razor blade. The volume of blood lost during the 20 min experiment was measured. After surgical suture of the tail wound, we let the mice recover from anesthesia. Platelet concentrations were counted 1 week before the experiments so that platelet counts were same between WT-chimeras and CLEC-2-chimeras.
Surface Plasmon Resonance Spectroscopy
Recombinant extracellular domain of human or mouse CLEC-2 expressed as a dimeric human or rabbit immunoglobulin Fc domain fusion protein (hCLEC-2-rFc2, mCLEC-2-rFc2) was generated as described previously (4) . A specific homophilic interaction between hCLEC-2-rFc2 or that between mCLEC-2-rFc2 was analyzed using a BIAcore X (BIAcore AB, Uppsala, Sweden). Ligands (αvβ3, α2β1, CD62P, LIMP-II, TSP-1, PEAR-1 (all purchased from R&D systems), hCLEC-2-rFc2, or mCLEC-2-rFc2) were covalently coupled to CM5 chip (BIAcore) using an Amine Coupling Kit (BIAcore) according to the manufacturer's instructions (20) . Regeneration of the protein-coated surfaces was achieved by running 10 μl of 10 mM HCL thorough the flow cell at 20 μl /min 2 times. A control surface was reacted with rFc2 and then blocked with ethanolamine.
Human CLEC-2-rFc2 or mouse CLEC-2-rFc2 in HBS-EP buffer (10 mM HEPES, 0.15 M NaCl, 3 mM EDTA, and 0.005% Tween 20, pH 7.4, BIAcore) at several concentrations was perfused over the control surface or an immobilized human CLEC-2-rFc2 surface or mouse CLEC-2-rFc2 surface at a flow rate of 20 μl/min at 25 °C, and the resonance changes were recorded. The response from the human CLEC-2-rFc2 surface or the mouse CLEC-2-rFc2 surface was subtracted from that of the control.
The dissociation constants (Kd) were determined using BIAevaluation software.
Results
Generation of CLEC-2-deficient mice.
A targeting vector to generate CLEC-2-deficient mice was designed so that a part of exon 1 flanked by two loxP sites could be deleted by expression of Cre protein (Supple. Figure 1A ). Nine ES clones were obtained, which contained the appropriately targeted allele, and were injected into C57BL/6 blastocycts. Southern blot analysis confirmed the presence of the targeted locus ( Figure 1A , 1B). Germline transmission was obtained from 6 independent ES cell clones (hereafter CLEC-2 flox/+). We crossed a CLEC-2 flox/+ mouse with a mouse that systemically expresses Cre recombinase to generate CLEC-2+/-mice. Germline transmission was confirmed by PCR and Southern blot. The heterozygous mice were phenotypically normal and were bred to obtain homozygous mice for the allele containing disrupted exon 1 of the CLEC-2 gene.
Genotype analysis of embryos from heterozygous intercrosses at day 13.5 gestation (E13.5) showed the expected numbers of CLEC-2-/-embryos. However, the percentage of the knockout embryos dropped to less than expected from E15.5 (Table 1) . We analyzed genotypes of 326 new born mice and found that the percentage of the knockout mice were only 9.8% (Suppl. Table. 1). Moreover, most of -/-pups died shortly after birth and only 2 -/-mice out of 326 mice survived after 8 weeks of age, suggesting that CLEC-2-/-mice are lethal at the embryonic/neonatal stage. There are fewer heterozygotes than that predicted by Mendelian inheritance (Suppl. Table. 1). We do not have any direct evidence to explain for this phenomenon. It is plausible that the heterozygotes may also have some developmental abnormality related to lymphatic vessels which causes intrauterine death to some pups. This needs further investigation.
CLEC-2-deficient mice exhibit disorganized vasculature and impaired lymphatic function.
To investigate the cause of embryonic or neonatal lethality of CLEC-2-deficient mice, we examined CLEC-2-/-embryos.
Cutaneous hemorrhagic appearance is the most striking phonotype observed in CLEC-2-lacking embryos ( Figure 1A) , which was first noted in E12.5 -E13.5. Edema was observed at the back skin in CLEC-2-deficient embryos ( Figure 1A , arrow), implying impaired lymphatic drainage. We assessed lymphatic function by infusing 2000 kDa dextran-FITC into embryonic limbs. Lymphangiography showed normal collecting lymphatic vessels immediately after dye infusion in wild-type mice at E17.5 ( Figure 1B upper inlet, arrow) , whereas dye uptake was not found even 10 min after injection ( Figure 1B, lower inlet) , suggesting functional defects in lymphatic drainage of CLEC-2-/-embryos.
Histological analysis of the mesentery of CLEC-2-deficient embryos revealed that peripheral blood cells were present within thin-walled vessels that stained for Lyve-1, a molecular marker of lymphatic endothelial cells, whereas there were no blood cells in Lyve-1-positive vessels in wild type embryos ( Figure  2A ). Triple fluorescent staining for SMA and PECAM-1 but not for Lyve-1 revealed that only blood vessels, but not lymphatic vessels contained blood cells in WT embryos ( Figure 2B ). On the other hand, lymphatic vessels as well as blood vessels contained blood cells in CLEC-2-deficient embryos ( Figure 2B ). These findings indicate that CLEC-2-deficient mice have blood-filled lymphatic vessels.
To investigate the network formation of blood vessels and lymphatic vessels, we performed whole-mount triple fluorescence confocal microscopy of embryonic back skin using antibodies to PECAM-1, Lyve-1, and Ter119 (a molecular marker of erythrocytes). Triple staining revealed that the dilated lymphatic vessels in CLEC-2-deficient embryos contain erythrocytes, whereas those of WT embryos did not contain blood, further confirming the blood-filled lymphatic vessels in CLEC-2-/-. In CLEC-2-deficient embryos, lymphatic vessels stained for Lyve-1 and PECAM-1 exhibited dilated, tortuous, and rugged appearance, which was in contrast to narrow, straight, and smooth appearance observed in WT embryos ( Figure 3A-3F ). This analysis also revealed anastomotic sites of blood and lymphatic vessels in CLEC-2-deficient embryos at E14.5 ( Figure  3I ) and at E17.5 ( Figure 3L ).
Upon CLEC-2 simulation of platelets with rhodocytin or podoplanin, the tyrosine kinase Src phosphorylates a single YXXL motif in its cytoplasmic domain. Then, the tyrosine kinase Syk binds to the phosphorylated YXXL motif by its SH2 domains, which leads to Syk activation, followed by tyrosine phosphorylation of adaptor proteins, SLP-76 and Linker for Activation of T cell (LAT). Phospholipase Cγ2 (PLCγ2) is finally activated, which results in Ca 2+ increase and platelet aggregation. We have previously reported that Src, Syk, LAT, SLP-76, and PLCγ2 are necessary for CLEC-2-mediated signal transduction (3, 21, 22) . Disorganized and blood-filled lymphatic vessels observed in CLEC-2-deficient embryos were also observed in embryos deficient in Syk, SLP-76 (10), or PLCγ2 (23).
These molecules are also necessary for signal transduction pathways mediated through the collagen receptor GPVI/FcRγ-chain.
However, blood-filled lymphatic vessels was not observed in mice-deficient in GPVI/FcRγ-chain, but only in CLEC-2-deficient mice, suggesting that platelet activation through CLEC-2, but not that through GPVI/FcRγ-chain, is important for lymph/blood vessel separation.
Taken together, we propose that CLEC-2 is essential for lymph/blood vessel separation, which is necessary for the survival of murine embryos.
Platelets deficient in CLEC-2 lacked rhodocytin-induced platelet activation, but showed normal responses to other agonists or extracellular matrices.
The next question is to investigate a role of CLEC-2 in thrombosis and hemostasis. Since CLEC-2-/-mice exhibited embryonic and neonatal lethality, we produced irradiated chimeric animals which had been rescued with fetal liver transplantation, in order to investigate a role of CLEC-2 in thrombosis and hemostasis. Mice rescued by wild type fetal liver was referred as WT-chimera, and those of CLEC-2-deficient fetal liver were referred as CLEC-2-chimeras hereafter. Immunoblotting ( Figure  4A ) and flow cytometry for CLEC-2 ( Figure 4B ) confirmed successful reconstitution. CLEC-2-deficient platelets expressed the major membrane proteins such as integrin αIIbβ3, α2β1, GPIb/IX/V, and PECAM-1 at the level similar to WT platelets (Suppl. Figure 2) .
In the process of physiological thrombus formation, the initial contact of platelets (tethering) to collagen exposed at sites of vessel injury is mediated predominantly by the interaction between platelet GPIb and VWF adhered to collagen, which is essential under high shear rates. In the second step, GPVI -collagen interactions initiate cellular activation followed by shifting of integrins to high-affinity state and the release of second-wave agonists, most importantly ADP and thromboxanes A2 (TxA2) (24) . Released ADP and TxA2 amplify integrin activation on adherent platelets and flowing platelets, which results in platelet-platelet interaction through activated integrin αIIbβ3 -fibrinogen interaction leading to thrombus growth. Therefore, we sought to investigate the responses of CLEC-2-deficient platelets to these agonists or extracellular matrices that participate in the physiologic thrombus formation.
CLEC-2-deficient platelets failed to aggregate in response to rhodocytin, a CLEC-2 activating snake venom, but they fully aggregated upon stimulation with other classical agonists including ADP, U46619, collagen, poly PHG (a GPVI-specific agonist peptide) (16) , and thrombin receptor PAR-4-activating peptide (PAR-4) ( Figure 4C ). Flow cytometric analysis of integrin αIIbβ3 activation and P-selectin exposure, a marker of α granule release, confirmed that CLEC-2 deficiency had no significant effect on platelets activation by ADP, U46619, poly PHG, and PAR-4, whereas responses to rhodocytin was abolished ( Figures 4D and 4E) . Similarly, serotonin release from dense granules induced by rhodocytin, but not by poly PHG or collagen was abolished in CLEC-2-deficient platelets ( Figure 4F ). Taken together, CLEC-2-deficiency results in the specific loss of CLEC-2-mediated signal transduction pathway in platelets, while leaving other pathways fully intact.
Platelets deficient in CLEC-2 showed normal adhesion and spreading on the surface of collagen, fibrinogen, laminin, and VWF.
It is well-known that platelets adhered and spread on the surface of various extracellular matrices, such as collagen, fibrinogen, laminin, and VWF through specific receptors (collagen: integrin α2β1 and GPVI, fibrinogen: integrin αIIbβ3, laminin: integrin α6 and GPVI, VWF: GPIb/IX/V and αIIbβ3). We next investigated the possibility that CLEC-2 is a receptor for these extracellular matrices and support platelet adhesion and spreading. As shown in Figure 5A , adhesion and spreading of CLEC-2-deficient platelets on the surface of these extracellular matrices were comparable to those of wild type platelets. Quantifications of platelet adhesion and spreading showed that there was no statistically significance difference between CLEC-2 deficient and wild type platelets ( Figure 5B ). These findings suggest that CLEC-2 is not an activation receptor for these extracellular matrices.
CLEC-2 is required for stable thrombus formation under flow
Platelet activation at sites of vascular injury under flow condition is an integrated process involving subendothelial matrices and soluble agonists including ADP, TxA2, and thrombin that supports adhesion and activation. To investigate a role of CLEC-2 in this process, whole blood from CLEC-2-chimeras or WT-chimeras labeled with DiOC6 was flowed over collagen-coated surfaces under high shear rate (2000 1/S) for 5 min. As shown in Figure 6A , B, C, WT platelets formed large thrombi on the surface of collagen by the end of perfusion period of 5 min, whereas thrombus formation of CLEC-2-deficient platelets was significantly impaired, suggesting that CLEC-2-dependent process is essential for stable aggregate formation under flow. CLEC-2-deficient platelets showed normal single cell adhesion on the surface of collagen ( Figure 5 ), whereas thrombus formation on the surface of collagen under flow condition was significantly inhibited ( Figure 6A , 6B, 6C). These findings taken together suggest that CLEC-2 is required for the piling-up process of platelets that leads to stable thrombus formation, but not for initial adhesion to collagen.
To investigate whether the thrombus instability was based on impaired platelet activation, we performed flow adhesion studies with or without coinfusion of ADP, which is released form activated platelets.
Coinfusion of 10 μM ADP into anticoagulated blood just before entering the capillary resulted in the formation of stable thrombi both in control and CLEC-2-deficient blood (supplemental figure 3) , suggesting that CLEC-2 functions as an activatory receptor in platelets that is required for stable thrombus formation.
In vivo thrombus formation was impaired in CLEC-2-Chimeras in a laser-induced injury model with minimal increase in tail bleeding.
Since platelet activation/aggregation is a major cause of arterial thrombosis, we studied the effects of CLEC-2-deficincy on pathological thrombus formation. We used a direct visual technique that enabled us to evaluate in vivo thrombus stability with great temporal and spatial resolution and to characterize the kinetics of CLEC-2-deficient platelets in thrombus formation. This method is based on confocal microscopy which permits high spatiotemporal resolution of individual platelets under flow conditions in mesenteric capillaries and arterioles (19, 25) . With this system, laser irradiation produces reactive oxygen species, which cause injury to the endothelial layer of the vessels. In WT-chimeras, after laser-induced injury to mesenteric capillaries, adherent platelets appeared to recruit platelets in circulation to form platelet aggregates, and the resultant thrombus reduced the vessel lumen diameter and blood flow velocity. Ultimately, the lumen was completely occluded by thrombi. In contrast, CLEC-2-deficient platelets adhered to the vessel wall more loosely than WT platelets, and they were frequently washed away by the blood flow and the platelet aggregates/thrombi never occluded the capillaries (Figure 7Ai , Supplemental videos 1 and 2). As a result, the number of CLEC-2 deficient platelets that accumulated at the injured vessel was 35% less than that of WT-platelets (Figure 7Aii, lower panel) . These findings suggest that CLEC-2 contributes to the stabilization of developing thrombi in the laser-injury model.
We next evaluated tail bleeding of WT-chimeras and CLEC-2-chimeras. Although CLEC-2-chimera had a tendency to have more blood loss from tail bleeding than WT-chimera, it was not significant ( Figure 7B , mean blood loss ± S.E.: 13.7 ± 1.3 μl in WT-chimera, 34.7 ± 3.2 μl in CLEC-2-chimera, P=0.08). These findings taken together suggest that CLEC-2-deficiency causes impaired thrombus growth with minimal increase in bleeding tendency.
CLEC-2 forms homophilic association
Thrombus formation under flow condition in vitro and in vivo is impaired in CLEC-2-chimeras, although CLEC-2-deficient platelets normally aggregated upon stimulation with classical agonists other than rhodocytin and showed normal adhesion and spreading on the surface of major extracellular matrices ( Figures  6, 7) . This suggests that the ligands of CLEC-2 may be present in plasma or on the surface of platelets. CLEC-2 is known to bind to podoplanin depending on glycosylation of podoplanin (4). Therefore, we first investigated the possibility of platelet membrane proteins with glycosylation, including CLEC-2 itself, as a candidate for CLEC-2 ligand(s). In order to directly prove the interaction between the molecules, we utilized surface plasmon resonance (BIAcore). Recombinant proteins of interest were perfused over the sensor tip coated with recombinant extracellular domain of human or mouse CLEC-2 expressed as a dimeric rabbit immunoglobulin Fc domain fusion protein (hCLEC-2-rFc2, mCLEC-2-rFc2). Several commercially-available recombinant proteins on the surface of platelet membrane, including integrin αvβ3, α2β1, CD62P, lysosomal integral membrane proteins-II (LIMP-II), thrombospondin-1, platelet endothelial aggregation receptor 1 (PEAR-1) were evaluated, but we could not observe their association with recombinant CLEC-2 (data not shown). Finally, we evaluated the CLEC-2 binding and, to our surprise, we detected homophilic interactions of hCLEC-2-rFc2 and mCLEC-2-rFc2 ( Figure 8A and 8B, respectively) . The sensorgrams at different analyte concentrations were obtained and normalized by subtracting background signals from the CLEC-2-Fc2 surface. The arrows indicate the beginning and end of perfusion of an analyte. After perfusion started, the resonance unit, which indicates the binding of analyte (flowing recombinant CLEC-2) to the ligand (coated recombinant CLEC-2), gradually increased, followed by a gradual decrease after the cessation of perfusion, suggesting that both human and mouse CLEC-2 forms homophilic association. The interaction between hCLEC-2-rFc2 molecules and that between mCLEC-2-rFc2 molecules were direct with an affinity of 2.78 ± 1.35 × 10 -7 M and 4.99 ± 1.29× 10 -7 M, respectively (n=4, Figure 8C ). To further confirm the homophilic association of CLEC-2 under more physiological condition, we investigated platelet adhesion of WT or CLEC-2-deficient platelets on the surface coated with mCLEC-2-rFc2 or rFc2. To exclude the possibility that the Fc portion interacts with a stimulatory Fc receptor, FcγRIIA, we used murine platelets, which lack FcγRIIA. As shown in Figure 9A and 9B, CLEC-2-deficient platelets adhered collagen-coated surfaces to the same extent as WT platelets, whereas platelet adhesion on the surface of mCLEC-2-rFc2 was greatly and significantly inhibited with CLEC-2-deficient platelets (p<0.005). These findings clearly suggest that CLEC-2 forms homophilic association. Since CLEC-2-deficient platelets still adhered to mCLEC-2-coated surfaces and the adhered platelets showed spreading to some extent, it is likely that there is another CLEC-2 ligand on the surface of platelets.
We next investigated whether soluble recombinant CLEC-2 binds to the surface of suspended platelets by flow cytometry. As shown in Figure 9C , the binding level of mCLEC-2-rFc2 to both WT platelets and CLEC-2-deficient platelets was virtually the same with that of the rFc2. However, there was a significant increase in mCLEC-2-rFc2 binding to both WT and CLEC-2-deficient platelets after platelet activation by PAR-4 peptides. However, it is important to note that the binding of mCLEC-2-rFc2 to activated WT platelets was significantly higher than that of activated CLEC-2-deficient platelets (p<0.05). These findings suggest that CLEC-2 binds more avidly to CLEC-2 on the surface of activated platelets, but there appears to be another CLEC-2 ligand on the surface of activated platelets.
Discussion
In this study using CLEC-2 deficient mice for the first time, we demonstrated that CLEC-2 is essential for blood/lymphatic vessel separation and thrombus formation in vivo through homophilic association. These findings imply that CLEC-2 is a potential target protein for the development of anti-platelet drugs and anti-metastatic drugs.
CLEC-2-deficient mice were lethal at the embryonic/neonatal stage with blood-filled, dilated, and tortuous lymphatic vessels which had anastomotic sites with blood vessels (lymph/blood vessel misconnection). It is assumed that higher pressure in blood vessels drove blood components into lymphatic vessels through the anastomotic sites, resulting in dilated lymphatic vessels and retention of erythrocytes in the periphery. Progenitor cells of vascular and lymphatic endothelial cells express PECAM-1 and its expression in differentiated lymphatic endothelial cells is depressed, as compared with vascular endothelial cells.
Although quantification has not been performed, we observed a higher level of PECAM-1 expression in the dilated lymphatic vessels in CLEC-2-deficient embryos than those of WT embryos ( Figure 3A, 3D, 3G, 3J ). It is plausible that blood flow from anastomosis may have led to high lymphatic pressure, which resulted in blood vessel endothelium-like change in lymphatic endothelial cells.
The mechanism by which CLEC-2 regulates blood/lymphatic vessel separation remains elucidated. Recently, Uhrin et al. have reported that platelet activation by podoplanin is a critical process for blood/lymphatic vessel separation (26) . They found that platelet aggregates build up at the separation zone of podoplanin-positive lymph-sacs and cardinal veins in wild-type embryos, but not in podoplanin-deficient embryos. Moreover, they proved that the same phenotypes are induced by anti-platelet drug, anti-podoplanin antibody, or inactivation of kindlin-3 gene required for platelet aggregation. We have previously found that podoplanin induces platelet aggregation through interaction with CLEC-2, and in this study we demonstrate that CLEC-2 deficiency leads to poor blood/lymphatic vessel separation. Their findings combined with ours imply that platelet aggregates generated by podoplanin-CLEC-2 interaction occlude the orifice of the lymph sacs, thereby inducing lymph/blood vessel separation. However, the phenotype of lymphatic vessels in podoplanin-deficient embryos is different from that of CLEC-2-deficient embryos; lymph/blood vessel misconnection disappears around 10-14 postnatal days in podoplanin-deficient mice, whereas the lymph/blood vessel misconnection is present persistently since E13.5 in CLEC-2-deficient mice. While the majority of CLEC-2-deficient mice were lethal, we were able to have two adult CLEC-2-deficient mice, both of which showed lymph/blood vessel misconnection phenotype (data not shown).
The differences between podoplanin deficiency and CLEC-2 deficiency with regards to lymph/blood vessel misconnection suggests that there is a ligand(s) other than podoplanin for CLEC-2 on the surface of lymphatic endothelial cells and their interactions also play a role in lymph/blood vessel separation. CLEC-2 is expressed in platelets, megakaryocytes, liver sinusoidal endothelial cells in humans and mice; however, it is also expressed in neutrophils in mice. Whether CLEC-2 in platelets, but not that of neutrophils, regulates lymph/blood vessel separation is now under investigation using conditional knockout mice that lack CLEC-2 only in platelets and megakaryocytes.
Although CLEC-2 plays a role in tumor metastasis, its powerful platelet activating ability and specific expression in platelets and megakaryocytes imply that CLEC-2 also plays an important role in thrombosis and hemostasis. CLEC-2 knockout mice should be utilized to accurately evaluate a role of CLEC-2 in thrombosis and hemostasis; however we found that CLEC-2-knockout mice are lethal at the embryonic/neonatal stage. We therefore generated radiation chimeric animals which had been rescued with transplantation of fetal liver taken from mice lacking CLEC-2. We observed significant inhibition of thrombus formation of CLEC-2-chimera under flow condition in vivo and in vitro, although platelet adhesion and spreading that is the initial step for thrombus formation remains intact.
Moreover, bleeding tendency was minimal with CLEC-2 chimera ( Figure 7B ), suggesting that low molecular weight compounds acting as CLEC-2 antagonists are ideal candidates for a novel anti-platelet drug that inhibits pathological thrombus formation, but not physiological hemostasis. CLEC-2 deficiency leads to lymph/blood misconnections in the developmental stage; however, this does not seem to be a problem for a CLEC-2 antagonist as anti-platelet drug is normally administrated to adults.
Recently, May et al. reported that anti-CLEC-2 antibody treatment of mice leads to the loss of CLEC-2 in circulating platelets for several days (27). These CLEC-2-deficient platelets displayed normal adhesion under flow, but subsequent aggregate formation was severely impaired in vitro and in vivo, revealing an essential function of CLEC-2 in hemostasis and thrombosis. While this unique study by May et al. shed light on the physiologic role of CLEC-2, there still remains room for criticism with antibody-induced removal of antigen from platelets; it may have certain undesirable effects. Extensive antigen-antibody interaction on the platelet membrane may have some effects on thrombus formation. Alternatively, antibody-induced platelet activation and subsequent release of secondary mediators may result in desensitization of platelets. In mice, CLEC-2 is also expressed on peripheral blood neutrophils and it mediates phagocytosis of antibody-coated beads and the production of proinflammatory cytokines, including TNF-α upon CLEC-2 stimulation (28). It is possible that the CLEC-2 antibody administered to mice may also work on CLEC-2 on neutrophils, thereby modifying cytokine generation and phagocytosis, which may affect thrombus formation under flow or in vivo. In fact, it has been reported that TNF-α inhibits thrombus formation (29) . Therefore, generation of CLEC-2-deficient mice has been awaited to solve these problems.
At our hand, CLEC-2 chimera showed only mild increase in tail bleeding, which was not statistically significant compared with WT-chimera ( Figure 7B ). In contrast to our findings, May et al. reported that CLEC-2 antibody-induced deficiency resulted in marked increase in bleeding time: bleeding stopped in all the control mice during 20 min observation period (mean bleeding time: 6.1 ± 3.1 min), whereas bleeding continued more than 20 min with 33% of CLEC-2-antibody-treated mice (for those, in which bleeding stopped, mean bleeding time: 10.8 ± 6.0 min). The discrepancy between gene-manipulated loss of antigen and antibody-induced loss has been reported previously; the bleeding time of GPVI/FcRγ-chain-deficient mice was not different from that of wild type mice (30), whereas antibody-induced GPVI-deficient mice showed significantly increased bleeding time (158 ± 89 sec in control vs. 330 ± 103 sec in antibody-treated mice), using the same protocol for the measurement of bleeding time.
The idea of antibody-induced knockout mice is derived from the previously-reported patients of idiopathic thrombocytopenic purpura (ITP). Sugiyama et al. and Moroi et al. reported that the ITP patients contained an antibody against GPVI that stimulates platelet aggregation, leading to loss of GPVI from the platelet surfaces (31, 32) . These ITP patients showed bleeding tendency as was the case in the antibody-induced GPVI-or CLEC-2-deficient mice, whereas genetically-modified GPVIor CLEC-2-deficient mice has no or less bleeding tendency. Although the precise mechanism for this discrepancy has not been elucidated, it is quite likely that antigen-antibody interaction induces some unexpected biologic responses, which may lead to overestimation of bleeding tendency due to loss of GPVI or CLEC-2.
Although it is demonstrated that CLEC-2 is essential for thrombus formation, the only known internal ligand of CLEC-2 up to date, podoplanin, is expressed in lymphatic endothelial cells or tumor cells and cannot be responsible for arterial thrombus formation. Thus, an important issue remains on how CLEC-2 support thrombus formation under flow in vitro and in vivo. From the findings of the previous paper and ours, it is suggested that the ligands of CLEC-2 is present in plasma or on the surface of activated platelets. We propose that CLEC-2 support thrombus formation, at least partly, through homophilic association, based on the following findings: 1) surface plasmon resonance detected homophilic association between recombinant CLEC-2, 2) platelet adhesion onto the surface coated with recombinant CLEC-2 was significantly attenuated with CLEC-2-deficient platelets, 3) the binding of soluble recombinant CLEC-2 was significantly attenuated with CLEC-2-deficient platelets. We found out that the interaction between human CLEC-2-hFc2 molecules is direct with an affinity of 2.78 × 10 -7 M, and that between mouse CLEC-2-rFc2 molecules is 4.99 × 10 -7
M (n=4). Christou et al. reported that CLEC-2 and podoplanin interact directly with an affinity of (2.45 ±0.37) × 10 -5 M (5), which apparently suggests that the affinity between CLEC-2 and podoplanin is much weaker than the homophilic CLEC-2 interaction. One may argue that it is intriguing that podoplanin-expressing cells induce platelet aggregation, whereas platelets which express CLEC-2 with high-affinity homophilic interacting property do not form spontaneous aggregates. However, Christou et al. used monomeric recombinant CLEC-2 with His tag, and used podoplanin-coated sensor chips (5), whereas we used dimeric recombinant CLEC-2 with Fc2, and the sensor chips were coated with this dimer form; we made dimeric CLEC-2, as it has been suggested that CLEC-2 exists as a dimeric form on cell surfaces (22, 33) . Since dimer forms of receptors are known to have much higher affinity to their ligands than single forms in the case of GPVI (34) , this apparent discrepancy in the affinity of CLEC-2 to ligands may be due to the different experimental conditions. Alternatively, recombinant CLEC-2 fixed on the surface may assume conformation which has higher homophilic activity than the natural CLEC-2 molecule on resting platelets, thereby giving a smaller Kd with surface resonance study. This hypothesis may be extended to allege that CLEC-2 has two forms, one with relatively low homophilic activity in resting platelets, and the other with high homophilic activity in activated platelets. In support to this hypothesis, soluble CLEC-2 binding to suspended platelets was observed only after platelet activation ( Figure 9C ). Moreover, surface expression of CLEC-2 was unaltered after stimulation (data not shown), suggesting higher homophilic binding activity of CLEC-2 in activated platelets. Additional experiments are awaited to address to these issues.
We also assume that there is other CLEC-2 ligand(s) on the surface of platelets than CLEC-2 itself. Although CLEC-2-deficient platelets showed reduced adhesion on the surface of recombinant CLEC-2 and reduced binding of soluble recombinant CLEC-2, it was not completely inhibited ( Figure 9 ). Moreover, CLEC-2-deficient platelets adhered to recombinant CLEC-2-coated surfaces showed spreading, suggesting that there is another ligand(s) for CLEC-2 on the surface of platelets, the binding to which leads to platelet activation and spreading.
In conclusion, we demonstrated using CLEC-2-deficient mice, that CLEC-2 is essential for blood/lymphatic vessel separation and thrombus formation in vivo through homophilic association. We also suggest for the possibility that there are other ligands for CLEC-2, which regulate lymphangiogenesis and thrombus formation. CLEC-2 can be a promising target protein for the development of anti-platelet drugs that inhibit pathological thrombus formation, but not physiological hemostasis
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Supplemental Video 1 In vivo thrombus formation of WT-chimera
After laser injury, platelets were adhered to vessel wall, followed by the recruitment of flowing platelets to the adhered platelets, and the resultant thrombus reduced the vessel lumen diameter and blood flow velocity. Just before complete vessel occlusion, bending red cells became visible due to reduced blood flow velocity.
Supplemental Video 2 In vivo thrombus formation of CLEC-2-chimera
Platelets were adhered to the vessel wall more loosely than WT-platelets and they are frequently washed away by the blood flow and the platelet aggregates never occluded the capillary. 4.99 ± 1.29
2.78 ± 1.35 mCLEC2 rFc2-mCLEC2 rFc2 mCLEC2 rFc2 100 μg/ml a: mCLEC2 rFc2 30 μg/ml b: mCLEC2 rFc2 1 μg/ml e: rFc2 10 μg/ml f: mCLEC2 rFc2 10 μg/ml c: 3 μg/ml d: mCLEC2 rFc2 hCLEC2 rFc2-hCLEC2 rFc2 hCLEC2 rFc2 100 μg/ml g : hCLEC2 rFc2 30 μg/ml h: hCLEC2 rFc2 1 μg/ml k: rFc2 10 μg/ml l: hCLEC2 rFc2 10 μg/ml i: 
